Project Grant R43CA217385

This $396,061 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to assess the efficacy of a novel class of hypoxia-inducible factor (HIF) inhibitors as a potential treatment for renal cell carcinoma (RCC). The principal investigator has developed boron-based HIF inhibitors derived from the natural compound honokiol, which have demonstrated promising anti-angiogenic properties in vitro. This 2-year project aims to (1) determine...

This $483,395 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by The Institute for Cancer Research (ICR) to investigate targeting the P300/CBP proteins as a potential novel therapeutic approach for treating renal cell carcinoma (RCC), the most common and lethal form of kidney cancer. The two-year grant funds preclinical studies to evaluate the therapeutic potential of inhibiting P300/CBP, which play a role in RCC...

The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $793,324 Project Grant to the Beckman Research Institute of the City of Hope to develop selective small molecule inhibitors against CYP8B1, a novel therapeutic target for treating hepatocellular carcinoma (HCC), including metabolic dysfunction associated HCC. The research aims to address the critical unmet need for innovative pharmacological therapies with desirable safety profiles and durable treatment effects for...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to the Dana-Farber Cancer Institute (DFCI) to investigate targeting the CDK4/6 pathway as a potential therapeutic strategy for translocation renal cell carcinoma (TRCC), an aggressive form of kidney cancer. The $267,298 award, effective from February 1, 2025 to January 31, 2027, will support in vitro and in vivo studies to test the sensitivity of TRCC cells to CDK4/6 inhibition,...

The National Cancer Institute (NCI) awarded a $371,905 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Florida to support research on the role of Angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (CCRCC). The project aims to define ANGPTL4's functions in the CCRCC tumor microenvironment, evaluate the efficacy of combining anti-ANGPTL4 antibodies with immune checkpoint inhibitors in mouse models, and determine ANGPTL4's cancer...

This Project Grant award, valued at $551,601.00 and provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), focuses on developing isoform-selective inhibitors targeting the 90 kDa heat shock protein (HSP90B) for the treatment of prostate cancer. The key objectives are to: Enhance the pharmacological properties of HSP90B-selective inhibitors for effective in vivo use against cancer, focusing on solubility, permeability, and half-life while preserving specificity....

The U.S. Department of Defense's Defense Health Agency awarded a $395,202 Project Grant to The University of Texas Southwestern Medical Center in Dallas, Texas under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "PET IMAGING OF HIF 2A IN RENAL CANCER," supports research to develop new imaging techniques for detecting and monitoring kidney cancer in military personnel and veterans. The three-year award, running from September 1, 2023 to August...

The Project Grant award of $319,693.00 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports research at the University of Texas Southwestern Medical Center, also known as Southwestern Medical School, to investigate the mechanisms of clear cell renal carcinoma. The research project, titled "DISSECTING THE MECHANISM OF SELECTIVE HIF-2 REGULATION OF PTHRP AND HYPERCALCEMIA IN CLEAR CELL RENAL CARCINOMA," aims to advance the...

The Dana-Farber Cancer Institute, Inc. was awarded a $166,726 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program. The two-year grant will support Selective Metabolic Dependencies in Kidney Cancer with Mitochondrial Mutations research from April 2021 through April 2023. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions. This award...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) provides $178,893 to the University of Pennsylvania to develop immunotherapy trials for renal cell carcinoma (RCC) that can be brought into the National Clinical Trials Network (NCTN). The principal investigator, Dr. Naomi Haas, is an expert in leading cooperative group, industry, and investigator-initiated trials for genitourinary cancers. The key initiatives under this 5-year award...